Glucagon promotes colon cancer cell growth via regulating AMPK and MAPK pathways

Takashi Yagi; Eiji Kubota; Hiroyuki Koyama; Tomohiro Tanaka; Hiromi Kataoka; Kenro Imaeda; Takashi Joh

doi:10.18632/oncotarget.24367

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Glucagon promotes colon cancer cell growth via regulating AMPK and MAPK pathways

Takashi Yagi, Eiji Kubota _, Hiroyuki Koyama, Tomohiro Tanaka, Hiromi Kataoka, Kenro Imaeda and Takashi Joh

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:10650-10664. https://doi.org/10.18632/oncotarget.24367

Metrics: PDF 1954 views | HTML 3184 views | ?

Abstract

Takashi Yagi1, Eiji Kubota1, Hiroyuki Koyama1, Tomohiro Tanaka1, Hiromi Kataoka1, Kenro Imaeda1 and Takashi Joh1

1Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Mizuho-ku, Nagoya 467-8601, Japan

Correspondence to:

Eiji Kubota, email: [email protected]

Keywords: glucagon; colon cancer; proliferation; incretin; glucagon signalling

Received: July 20, 2017 Accepted: January 19, 2018 Published: January 31, 2018

ABSTRACT

Cancer is one of the major causes of death in diabetic patients, and an association between antidiabetic drugs and cancer risk has been reported. Such evidence implies a strong connection between diabetes and cancer. Recently, glucagon has been recognized as a pivotal factor implicated in the pathophysiology of diabetes. Glucagon acts through binding to its receptor, glucagon receptor (GCGR), and cross-talk between GCGR-mediated signals and signaling pathways that regulate cancer cell fate has been unveiled. In the current study, expression of GCGR in colon cancer cell lines and colon cancer tissue obtained from patients was demonstrated. Glucagon significantly promoted colon cancer cell growth, and GCGR knockdown with small interfering RNA attenuated the proliferation-promoting effect of glucagon on colon cancer cells. Molecular assays showed that glucagon acted as an activator of cancer cell growth through deactivation of AMPK and activation of MAPK in a GCGR-dependent manner. Moreover, a stable GCGR knockdown mouse colon cancer cell line, CMT93, grew significantly slower than control in a syngeneic mouse model of type 2 diabetes with glycemia and hyperglucagonemia. The present observations provide experimental evidence that hyperglucagonemia in type 2 diabetes promotes colon cancer progression via GCGR-mediated regulation of AMPK and MAPK pathways.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24367

Publication Alerts

Oncoscience

Post-Publication Promotion

Research Papers:

Glucagon promotes colon cancer cell growth via regulating AMPK and MAPK pathways

Abstract